Barclays PLC Acquires 329,870 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Barclays PLC raised its stake in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 154.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 543,336 shares of the biotechnology company's stock after acquiring an additional 329,870 shares during the quarter. Barclays PLC owned approximately 0.08% of OPKO Health worth $810,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in OPK. Rubric Capital Management LP lifted its holdings in OPKO Health by 9.6% during the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company's stock worth $72,573,000 after buying an additional 4,284,336 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of OPKO Health by 142.5% during the third quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company's stock valued at $2,227,000 after acquiring an additional 876,272 shares during the period. Squarepoint Ops LLC bought a new position in OPKO Health in the second quarter valued at about $592,000. BNP Paribas Financial Markets increased its position in OPKO Health by 736.7% in the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company's stock worth $368,000 after purchasing an additional 217,450 shares during the period. Finally, Intech Investment Management LLC bought a new stake in OPKO Health during the 3rd quarter worth about $190,000. Institutional investors and hedge funds own 64.63% of the company's stock.

OPKO Health Trading Up 0.3 %

OPKO Health stock traded up $0.01 during midday trading on Thursday, hitting $1.48. 1,037,949 shares of the stock were exchanged, compared to its average volume of 2,867,444. The stock has a market capitalization of $1.01 billion, a PE ratio of -7.76 and a beta of 1.63. The company has a fifty day simple moving average of $1.54 and a two-hundred day simple moving average of $1.50. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. OPKO Health, Inc. has a 52 week low of $0.86 and a 52 week high of $1.76.

Analyst Ratings Changes

OPK has been the topic of several recent research reports. HC Wainwright reaffirmed a "buy" rating and issued a $3.00 target price on shares of OPKO Health in a research note on Wednesday, January 8th. StockNews.com cut shares of OPKO Health from a "hold" rating to a "sell" rating in a research note on Wednesday. Finally, Barrington Research reissued an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a research note on Friday, November 8th.

Insiders Place Their Bets

In other news, CEO Phillip Md Et Al Frost bought 500,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was purchased at an average price of $1.48 per share, for a total transaction of $740,000.00. Following the acquisition, the chief executive officer now owns 213,036,477 shares in the company, valued at approximately $315,293,985.96. This trade represents a 0.24 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last three months, insiders have bought 1,804,255 shares of company stock worth $2,764,605. Company insiders own 47.26% of the company's stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.